{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:29:31Z","timestamp":1778178571041,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ihj.2024.01.018","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T03:39:08Z","timestamp":1707363548000},"page":"S96-S100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["Management of dyslipidemia in special groups"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7071-2447","authenticated-orcid":false,"given":"Jayagopal","family":"P B","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prafulla G.","family":"Kerkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2024.01.018_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.ihj.2024.01.018_bib2","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/eurheartj\/ehv072","article-title":"The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials","volume":"36","author":"Preiss","year":"2015","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ihj.2024.01.018_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171168","article-title":"No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials","volume":"12","author":"Al-Gobari","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ihj.2024.01.018_bib4","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ejhf.247","article-title":"Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF","volume":"17","author":"Feinstein","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ihj.2024.01.018_bib5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12944-019-1135-z","article-title":"Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis","volume":"18","author":"Bielecka-Dabrowa","year":"2019","journal-title":"Lipids Health Disease"},{"issue":"18","key":"10.1016\/j.ihj.2024.01.018_bib6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ihj.2024.01.018_bib7","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ihj.2024.01.018_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.23736\/S0026-4784.18.04330-7","article-title":"Dyslipidemia in pregnancy and maternal-fetal outcome","volume":"71","author":"Nasioudis","year":"2019","journal-title":"Minerva Ginecol"},{"issue":"1","key":"10.1016\/j.ihj.2024.01.018_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12944-019-1180-7","article-title":"Hypertriglyceridemia triggered acute pancreatitis in pregnancy - diagnostic approach, management and follow-up care","volume":"19","author":"Cruciat","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"7","key":"10.1016\/j.ihj.2024.01.018_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11883-022-01030-w","article-title":"Dyslipidemia management in pregnancy: why is it not covered in the guidelines?","volume":"24","author":"Lewek","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"10.1016\/j.ihj.2024.01.018_bib11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacl.2016.07.002","article-title":"The risks of statin use in pregnancy: a systematic review","volume":"10","author":"Karalis","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.ihj.2024.01.018_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MOL.0000000000000790","article-title":"Management of familial hypercholesterolemia in pregnancy","volume":"32","author":"Graham","year":"2021","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"10.1016\/j.ihj.2024.01.018_bib13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jceh.2021.11.010","article-title":"Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis","volume":"12","author":"Shalimar","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.ihj.2024.01.018_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"9","key":"10.1016\/j.ihj.2024.01.018_bib15","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.mayocp.2022.04.005","article-title":"Nonalcoholic fatty liver disease: review of management for primary care providers","volume":"97","author":"Basu","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.ihj.2024.01.018_bib16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/17474124.2022.2119128","article-title":"Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals","volume":"16","author":"Ng","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"8A","key":"10.1016\/j.ihj.2024.01.018_bib17","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.ihj.2024.01.018_bib18","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","article-title":"Statin use in patients with cirrhosis: a retrospective cohort study","volume":"59","author":"Kumar","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.ihj.2024.01.018_bib19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ihj.2024.01.018_bib20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.29172","article-title":"Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study","volume":"66","author":"Chang","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ihj.2024.01.018_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12876-019-1147-1","article-title":"Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"10.1016\/j.ihj.2024.01.018_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11894-017-0584-7","article-title":"Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects","volume":"19","author":"Vargas","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.ihj.2024.01.018_bib23","series-title":"Clinical and Research Information on Drug-Induced Liver Injury [Internet]","author":"LiverTox","year":"2012"},{"key":"10.1016\/j.ihj.2024.01.018_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12916-022-02288-2","article-title":"Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)","volume":"20","author":"Cho","year":"2022","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.ihj.2024.01.018_bib25","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","article-title":"Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study","volume":"12","author":"Oscarsson","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ihj.2024.01.018_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5805398","article-title":"Liver protective effect of fenofibrate in NASH\/NAFLD animal models","volume":"2022","author":"Mahmoudi","year":"2022","journal-title":"PPAR Res"},{"issue":"17","key":"10.1016\/j.ihj.2024.01.018_bib27","doi-asserted-by":"crossref","first-page":"E442","DOI":"10.1503\/cmaj.190848","article-title":"Calibration and discrimination of the Framingham risk score and the pooled cohort equations","volume":"192","author":"Ko","year":"2020","journal-title":"CMAJ"},{"issue":"48","key":"10.1016\/j.ihj.2024.01.018_bib28","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1093\/eurheartj\/ehv734","article-title":"Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis","volume":"37","author":"Gili","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2024.01.018_bib29","series-title":"Evidence-Based Review of Statin Use in Patients with HIV on Antiretroviral Therapy. Expert Analysis","author":"Hiremath","year":"2018"},{"issue":"159","key":"10.1016\/j.ihj.2024.01.018_bib30","first-page":"49","article-title":"Role of dyslipidemia in accelerating inflammation, autoimmunity, and atherosclerosis in systemic lupus erythematosus and other autoimmune diseases","volume":"30","author":"Wang","year":"2020","journal-title":"Discov Med"},{"issue":"1","key":"10.1016\/j.ihj.2024.01.018_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcct.2021.06.003","article-title":"Chronic inflammatory diseases and coronary heart disease: insights from cardiovascular CT","volume":"16","author":"Patel","year":"2022","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.ihj.2024.01.018_bib32","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s10067-018-4169-0","article-title":"Recognition and control of hypertension, diabetes, and dyslipidemia in patients with sytemic lupus erythematosus","volume":"37","author":"Castro","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ihj.2024.01.018_bib33","series-title":"The Effect of Inflammation and Infection on Lipids and Lipoproteins","author":"Feingold","year":"2000"},{"issue":"9","key":"10.1016\/j.ihj.2024.01.018_bib34","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/art.40892","article-title":"A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA)","volume":"71","author":"Kitas","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ihj.2024.01.018_bib35","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0961203312450084","article-title":"Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect","volume":"21","author":"Cairoli","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.ihj.2024.01.018_bib36","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1021\/acs.jproteome.8b00192","article-title":"NMR-based serum metabolomics reveals reprogramming of lipid dysregulation following cyclophosphamide-based induction therapy in lupus nephritis","volume":"17","author":"Guleria","year":"2018","journal-title":"J Proteome Res"},{"key":"10.1016\/j.ihj.2024.01.018_bib37","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/j.1600-6143.2011.03763.x","article-title":"The PROMISE study: a phase 2b multicenter study of Voclosporin (ISA247) versus tacrolimus in de novo Kidney transplantation","volume":"11","author":"Busque","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ihj.2024.01.018_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2004.04.005","article-title":"Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients","volume":"101","author":"Launay-Vacher","year":"2005","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ihj.2024.01.018_bib39","article-title":"REDUCE-IT investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","author":"Bhatt","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2024.01.018_bib40","series-title":"Endotext","article-title":"Cholesterol lowering drugs","author":"Feingold","year":"2021"},{"issue":"1","key":"10.1016\/j.ihj.2024.01.018_bib41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12906-019-2777-0","article-title":"Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials","volume":"19","author":"Yang","year":"2019","journal-title":"BMC Complement Altern Med"},{"issue":"1","key":"10.1016\/j.ihj.2024.01.018_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-022-08921-5","article-title":"Risk and protective factors for COVID-19 morbidity, severity, and mortality","volume":"64","author":"Zhang","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ihj.2024.01.018_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/heartjnl-2020-317901","article-title":"Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis","volume":"107","author":"Bae","year":"2021","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.ihj.2024.01.018_bib44","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.4103\/jfmpc.jfmpc_2273_21","article-title":"Clinico-epidemiological profile and outcomes of adults with COVID-19: a hospital-based retrospective study in Kerala, India","volume":"11","author":"Anand","year":"2022","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.ihj.2024.01.018_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.1019970","article-title":"Editorial: dyslipidemia, obesity and coronavirus disease 2019 (COVID-19)","volume":"9","author":"Hariyanto","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.ihj.2024.01.018_bib46","series-title":"Lipid and Lipoprotein Levels in Patients with COVID-19 Infections","author":"Feingold","year":"2000"},{"issue":"5","key":"10.1016\/j.ihj.2024.01.018_bib47","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.dsx.2020.07.054","article-title":"Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection","volume":"14","author":"Hariyanto","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"10.1016\/j.ihj.2024.01.018_bib48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12985-022-01865-4","article-title":"High-density lipoproteins may play a crucial role in COVID-19","volume":"19","author":"Nain","year":"2022","journal-title":"Virol J"},{"issue":"6","key":"10.1016\/j.ihj.2024.01.018_bib49","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jacl.2020.09.002","article-title":"Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia","volume":"14","author":"Kayikcioglu","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.ihj.2024.01.018_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S2213-8587(22)00389-8","article-title":"Blood lipids after COVID-19 infection","volume":"11","author":"Durrington","year":"2023","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948322400018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948322400018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T01:38:43Z","timestamp":1712626723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001948322400018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":50,"alternative-id":["S001948322400018X"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2024.01.018","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of dyslipidemia in special groups","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2024.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}